Geode Capital Management LLC Purchases 171,774 Shares of Moderna, Inc. (NASDAQ:MRNA)

Geode Capital Management LLC increased its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,241,354 shares of the company's stock after buying an additional 171,774 shares during the quarter. Geode Capital Management LLC owned approximately 1.88% of Moderna worth $300,219,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter worth $37,000. Crowley Wealth Management Inc. acquired a new position in shares of Moderna in the fourth quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after purchasing an additional 389 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 8.4 %

NASDAQ:MRNA traded down $2.24 on Thursday, hitting $24.43. The company had a trading volume of 4,643,981 shares, compared to its average volume of 7,105,071. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The stock has a market capitalization of $9.44 billion, a price-to-earnings ratio of -2.64 and a beta of 2.23. The firm has a 50 day moving average of $31.96 and a two-hundred day moving average of $41.54.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages recently commented on MRNA. UBS Group decreased their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Argus downgraded Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. Bank of America decreased their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.